nectar lifesciences has accepted the resignation of Dr. Surulichamy Senthilkumar as a Non-Executive Non-Independent Director of the Company, effective August 06, 2026. The departure marks a change in the Board composition, with the director citing pre-occupations and other personal reasons for his decision to step down. This development is relevant to shareholders monitoring governance structures and Board continuity at the firm.

The resignation was formalized through a letter dated August 06, 2026, submitted by Dr. Surulichamy Senthilkumar (DIN: 11124083). In his communication to the Board of Directors, he confirmed that there are no material reasons for his resignation other than those explicitly stated in the letter. The Company Secretary & Compliance Officer, Sanjaymohan Singh Rawat, signed the disclosure filed with the stock exchanges on the same date.

The filing was made pursuant to Regulation 30 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additionally, the disclosure adheres to SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and its subsequent amendments. These regulatory frameworks mandate timely disclosure of changes in the Board’s composition to ensure transparency for investors.

Resignation Details

The following table outlines the specific details of the resignation as disclosed in Annexure A of the filing:

Dr. Surulichamy Senthilkumar served as a Non-Executive Non-Independent Director. His resignation takes effect from the closing hours of August 06, 2026. The Company has attached the letter of resignation along with detailed reasons to the exchange filings for ready reference.

Governance Implications

The exit of a Non-Executive Non-Independent Director may prompt the Board to consider appointing a successor to maintain adequate representation and expertise. However, no immediate plans for replacement were disclosed in this filing. Investors should monitor future announcements regarding any new appointments or changes to Board committees that Dr. Surulichamy Senthilkumar may have been part of, although such committee memberships were not specified in the current disclosure.

nectar lifesciences has completed the disposal of its non-core Narbada Industries unit, selling land, structures, and plant machinery to Shree Balaji Cold Chain & Storage Services for a total consideration of ₹11.22 crore. The transaction, finalized on August 04, 2026, removes an inoperative asset from the company’s balance sheet, streamlining operations without impacting core revenue streams. The sale price significantly exceeds the book value of the investment, indicating a potential gain on de-recognition.

The deal was structured in two components: the surrender of leasehold rights for the land and structures situated in Jammu, and the separate sale of plant and machinery located at the premises. Nectar Lifesciences received ₹9.60 crore for the leasehold rights and ₹1.62 crore for the machinery, plus applicable taxes. The company confirmed that Narbada Industries had been inoperative, classifying these assets as non-core. This strategic divestment aligns with efforts to optimize asset utilization by exiting dormant business lines.

Regulatory filings submitted to the National Stock Exchange of India Limited and BSE Limited disclose that the transaction does not constitute a related party transaction. The purchaser, M/s Shree Balaji Cold Chain & Storage Services, is not affiliated with the promoters or group companies of Nectar Lifesciences. The agreement was entered into and completed on August 04, 2026, with all necessary deeds executed on the same date. Sanjaymohan Singh Rawat, Company Secretary & Compliance Officer, signed the disclosure pursuant to Regulation 30 of the SEBI LODR Regulations.

The financial impact of the disposal is minimal in terms of revenue contribution but notable for balance sheet cleanup. During financial year 2025-26, the Narbada Industries unit generated zero revenue, contributing 0.00% to the company’s total income. However, the investment value stood at ₹217.69 lakhs, representing 0.37% of the company’s net worth as of March 31, 2026. The sale proceeds of ₹11.22 crore against a book value of ₹217.69 lakhs suggest a substantial return on the divested capital.

Transaction Details

What the Numbers Show

The disparity between the book value and the sale consideration highlights the latent value in the company’s idle assets. While the Narbada Industries unit contributed no operational revenue, its underlying real estate and equipment held significant market value. By converting this illiquid, non-core investment into cash, Nectar Lifesciences improves its liquidity position without disrupting ongoing pharmaceutical or healthcare operations. The absence of related-party involvement ensures the transaction was conducted at arm's length, validating the commercial fairness of the ₹11.22 crore valuation.